BPA Call 36C24122A0124-36C24125N0234
Award Date
12/6/24
Potential Completion Date
7/14/25
Potential Value
$6K
Federal Agency
Veterans Integrated Service Network 1
Ultimate Awardee
Not listed
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Haven, CT 06516, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide ClonoSEQ minimal residual disease testing services for the Boston and West Haven VA health care systems. The contract has a ceiling value of $95,000.00 and a period of performance through July 2026. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products, and...
This is a firm fixed price contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, for ClonoSEQ minimal residual disease testing services. The $165,700 contract has a performance period ending July 14, 2025 and is a call under a larger $828,750 single award blanket purchase agreement (BPA) from the VA's Veterans Integrated Service Network 1 for ClonoSEQ services benefiting VA medical...
This is a firm fixed price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 1 (VISN 1) to Adaptive Biotechnologies Corporation, doing business as Adaptive, for ClonoSEQ minimal residual disease testing services. The $9,750 contract call has a performance period through July 2023 and is part of a larger $828,750 single award BPA for ClonoSEQ services benefiting VA medical facilities in the New England region. The BPA...
This is a firm fixed price contract awarded by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, for ClonoSEQ minimal residual disease testing services. The contract, with a ceiling value of $9,750.00, is a call under a $828,750.00 single award blanket purchase agreement held by Adaptive with the VA's Veterans Integrated Service Network 1 for a 5-year ordering period ending in July 2027. The contract supports VA medical facilities in the...
This federal contract award was made by the Defense Health Agency to Adaptive Biotechnologies Corporation, a commercial provider of immune-driven medicine services and products based in Seattle, Washington. The $224,250 firm fixed-price purchase order is for Adaptive's ClonoSEQ in-vitro diagnostic test service that has received Food and Drug Administration clearance for detecting blood cancer in patients. The contract has a period of performance through February 27, 2030 and is not set aside for...
This is a $385,920 firm fixed price definitive contract awarded by the Defense Health Agency to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide the ClonoSEQ Minimal Residual Disease In-Vitro Diagnostic Array for the Department of Pathology at the Walter Reed National Military Medical Center. The contract has a performance period ending on February 28, 2025 and does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven...
This is a federal contract award to Adaptive Biotechnologies Corporation, a for-profit organization based in Seattle, Washington. The contract is for ClonoSEQ FDA-cleared in vitro diagnostic (IVD) testing services, with a ceiling value of $681,270.00. The contract was awarded by the Defense Health Agency, a defense agency, on March 14, 2025, with a final completion date of March 13, 2030. The contract is a definitive contract with a firm fixed-price pricing type. There is no set-aside...
This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, to Adaptive Biotechnologies Corporation (also doing business as Adaptive) for IMMUNOSEQ MMTCRB SERVICE. The contract, valued at $12,200.00, does not have a set-aside designation. Through this award, Adaptive Biotechnologies will provide specialized sequencing and testing services to support HHS research programs. Adaptive...
The U.S. Defense Health Agency (DHA) has awarded a $76,200 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for adaptive immunosequencing services. The award does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products. The company has previously received awards from the Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) to provide...
This is a firm fixed price purchase order valued at $234,900.00 awarded by the National Institutes of Health (NIH) Clinical Center to Adaptive Biotechnologies Corporation, doing business as Adaptive, with a period of performance ending on September 30, 2024. The contract does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products, including immunosequencing, DNA extraction, and COVID-19 research services for the...